FET in Adenomyosis (ADY)

January 23, 2026 updated by: Indira IVF Hospital Pvt Ltd

Is GnRH Agonist Plus Letrozole a Better Choice Than GnRH Agonist Alone in Adenomyosis Cases Undergoing Frozen Embryo Transfer?

Purpose of the Study:

To compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET).

Research Question:

Is the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET?

Hypothesis:

Null Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET.

Study Outcomes:

Primary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

700

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • India
    • Rajasthan
      • Udaipur, Rajasthan, India, 313001
        • Indira IVF Pvt Hospital
        • Sub-Investigator:
          • Akanksha Jangid, MD
        • Contact:
        • Principal Investigator:
          • Taruna Jhamb, MD
        • Sub-Investigator:
          • Peter Humaidan, DMSc
        • Sub-Investigator:
          • Vipin Chandra, DGO
        • Sub-Investigator:
          • Snehadarshani Karnath, MD
        • Sub-Investigator:
          • Yasha Pandey, MD
        • Sub-Investigator:
          • Pawan Yadav, MD
        • Sub-Investigator:
          • Pooja Shinde, DNB
        • Sub-Investigator:
          • Nisha Tiwari, DNB
        • Sub-Investigator:
          • Tanu Batra, DNB
        • Sub-Investigator:
          • Amol Lunkad, MD
        • Sub-Investigator:
          • Rinoy Sreedharan, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Diagnosis of adenomyosis confirmed via transvaginal ultrasound as per MUSA criteria History of infertility requiring frozen embryo transfer (FET). Availability of at least one good-quality frozen embryo for transfer

Exclusion Criteria:

BMI ≥ 30 kg/m2 Presence of endocrine disorders; (uncontrolled diabetes mellitus, / hyperprolactinemia, thyroid dysfunction, Congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome Previous major uterine surgery Gestational carrier Fertility preservation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group B
Drug: GnRH agonist and Letrozole
Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts
Active Comparator: Group A
Drug: GnRH agonist downregulation
Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ongoing pregnancy rate
Time Frame: 12 weeks of gestation

Presence of gestational sacs with a heartbeat at the 12th gestational week. The ongoing pregnancy rate will be calculated using the below formula.

Ongoing pregnancy rate: (the number of ongoing pregnancy cases/the number of clinical pregnancy cases) × 100%
12 weeks of gestation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implantation Rate
Time Frame: 4 weeks after embryo transfer

The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred. The implantation rate will be calculated using the below formula.

Implantation rate: (The number of gestational sacs observed/ number of embryos transferred) × 100
4 weeks after embryo transfer
Chemical Pregnancy rate
Time Frame: 4 weeks after embryo transfer
Detection of a fetal heartbeat on transvaginal ultrasound at the 6th gestational week. The clinical pregnancy rate will be calculated using the below formula.
4 weeks after embryo transfer
Biochemical loss rate
Time Frame: 4 weeks after embryo transfer

Pregnancies diagnosed only by β-human chorionic gonadotropin detection without a gestational sac visualized by vaginal ultrasound at the 6th gestational week. The biochemical loss rate will be calculated using the below formula.

Biochemical loss rate: (the number of biochemical pregnancy loss cases/the number of women per group) × 100%
4 weeks after embryo transfer
1st trimester loss
Time Frame: 12 weeks of gestation
First-trimester loss refers to the spontaneous loss of a pregnancy occurring before the end of the 12th week of gestation
12 weeks of gestation
2nd trimester loss
Time Frame: 20 weeks of gestation
Second-trimester loss refers to the spontaneous loss of a pregnancy occurring between 13 and 20 weeks of gestation.
20 weeks of gestation
Live Birth Rate
Time Frame: Post delivery after completion of 20 weeks of gestation

The number of deliveries that resulted in at least one live birth per 100 Embryo transferred cycle.

Live birth rate: (The number of live births / the number of embryos transferred cycle) × 100
Post delivery after completion of 20 weeks of gestation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Indira IVF Hospital Pvt Ltd

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 25, 2026

Primary Completion (Estimated)

July 15, 2026

Study Completion (Estimated)

December 23, 2026

Study Registration Dates

First Submitted

March 29, 2025

First Submitted That Met QC Criteria

March 29, 2025

First Posted (Actual)

April 6, 2025

Study Record Updates

Last Update Posted (Actual)

January 26, 2026

Last Update Submitted That Met QC Criteria

January 23, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IIHL/UDR/P/003_2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

he Individual Participant Data (IPD) will be shared with authorized researchers upon request. The supporting documents, including the study protocol, SAP, and ICF, will be provided alongside the IPD to ensure comprehensive understanding and proper data interpretation.

When: IPD will be available after the completion of the study and publication of primary results.

How: IPD will be shared through a secure data repository or via encrypted files sent through secure email upon request, following proper data use agreements.

IPD Sharing Time Frame

After publication

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adenomyosis

Clinical Trials on GnRH agonist downregulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe